

Protective immunity against *Eimeria tenella* infection in chickens following oral immunization with *Bacillus subtilis* expressing *Eimeria tenella* 3-1E protein

Zhiwei Lin¹ · Yanyun Shi¹ · Bin Deng¹ · Xiangfei Mao¹ · Dongyou Yu¹ · Weifen Li¹

Received: 6 February 2015 / Accepted: 6 May 2015 / Published online: 22 May 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract The current experiment was conducted to construct recombinant *Bacillus subtilis* WB600 expressing *Eimeria tenella* 3-1E protein to investigate the oral immunization protective effects against *E. tenella*. The merozoite surface antigen 3-1E gene of *E. tenella* was introduced into the *pBS-H1* expression vector with a novel signal peptide sequence. After the electro-transformation, the expression of objective protein in *B. subtilis* WB600 was detected by Western blot. The results showed that the recombinant *B. subtilis* strain with the ability of high-level secretion of 3-1E was constructed successfully. Seven-day-old broiler chickens were orally vaccinated with *B. subtilis* WB600 harboring 3-1E (*B.S-pBS-H1-3-1E*) or *B. subtilis* WB600 with empty plasmid (*B.S-pBS-H1*) 10 days prior to challenge with sporulated *E. tenella* oocysts. The results showed the recombinant *B. subtilis* strain with the ability of high-level secretion of 3-1E was constructed successfully. Vaccination with *B.S-pBS-H1-3-1E* strain significantly increased the anti-coccidial index and reduced cecal lesion scores compared with the positive control group (chickens were challenged with sporulated *E. tenella* oocysts without

oral administration of *B.S-pBS-H1-3-1E* strain) and *B.S-pBS-H1* group. Ceca mucosal sIgA, secretion, and IL-2, IL-12, IFN- γ , and IL-10 level after challenge were greater in the *B.S-pBS-H1-3-1E* group than in the positive control group. Taken together, these results indicated that *B. subtilis* WB600 harboring 3-1E protein induces protective immunity against *E. tenella*.

Keywords *Bacillus subtilis* · Chickens · *Eimeria tenella* · Oral immunization · 3-1E protein

Introduction

Coccidiosis is a widespread intestinal tract infectious disease caused by at least seven *Eimeria* species in poultry industry (Jang et al. 2010). *Eimeria tenella* is one of the most pathogenic and serious, in terms of the distribution, outbreak frequency, and economic losses (McDougald and Reid 1991; Abi-Ghanem et al. 2008). Currently, the main methods to control the disease are drugs and live vaccines. However, because of increasing problems with prolonged drug usage and high cost of vaccines, there is an urgent need for more effective and safer alternative strategies for control of coccidiosis (Dalloul et al. 2006; Williams 2006; Lee et al. 2007). Many secreted or membrane-bound proteins of *Eimeria* involved in the interaction with the host immune system are considered as candidates for immunological interventions (Ma et al. 2013). 3-1E antigen is a 20-kDa protein of *Eimeria* that is highly immunogenic and conserved, inducing partial protection against avian coccidiosis (Lillehoj and Lillehoj 2000). Therefore, it can be used as vaccine candidate.

Genetically engineering live vector vaccine expressing different target antigens via mucosal routes has successfully induced protective immunity against a variety of infectious

Zhiwei Lin and Yanyun Shi contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s00436-015-4539-3) contains supplementary material, which is available to authorized users.

✉ Dongyou Yu
dyyu@zju.edu.cn

✉ Weifen Li
wfli@zju.edu.cn

¹ Key Laboratory of Molecular Animal Nutrition, Ministry of Education, College of Animal Sciences, Zhejiang University, 388 Yuhangtang Road, West Lake District Hangzhou 310058, People's Republic of China

disease including avian coccidiosis. However, due to transit of strain through the mammalian gastrointestinal tract and low antigen loads particularly after deliver via mucosal routes, the limited immunogenicity of both spores and cells has been questioned (Song et al. 2000; Min et al. 2001; Lee et al. 2010a). Recently, several heterologous antigens have been successfully adapted to *Bacillus subtilis* as vectors eliciting both systemic and secreted antibody, as well as cellular immune response to the passenger antigens following oral or parenteral administration to organism (Paccez et al. 2006, 2007; Fu et al. 2008; Luiz et al. 2008; Lee et al. 2010b).

B. subtilis has been explored as a tool for expression and delivery of antigen proteins due to the superior capacity of secreting proteins, lacking pathogenicity, propagating quickly, forming spores, and stimulating the immune system (Fu et al. 2008, 2011; Tseng et al. 2009).

A study has been designed to construct a recombinant *B. subtilis* expression vector with a processing-efficient signal peptide sequence to achieve high-level secretion of 3-1E in *B. subtilis*. Subsequently, another trial was taken to evaluate immunogenicity and protective effects of this recombinant *B. subtilis* strain against *E. tenella* in broiler chickens after oral vaccination.

Materials and methods

Bacterial strains and growth conditions

B. subtilis WB600 ($\Delta nprE \Delta aprE \Delta epr \Delta bpf \Delta mpr \Delta nprB$) was used in all experiments. WB600 was routinely grown in Luria-Bertani (LB) medium (1 % tryptone, 0.5 % yeast extract, and 1 % NaCl, pH 7.5). To express the protein, wild-type and recombinant *B. subtilis* strains were grown in LB containing kanamycin (10 μ g/ml) in Erlenmeyer flasks. Sporulation of the *B. subtilis* strain was induced in Difco sporulation media (DSM) using the exhaustion method as preciously described (Nicholson and Setlow 1990).

Recombinant plasmids construction

About 0.1 g ($\times 10^7$) sporulated oocysts of *E. tenella* were grinded to sporozoites in mortar on ice. Oocyst purification, sporulation, and excystation were done as Chapman and Shirley (2003) described. Total RNA was extracted from sporulated oocysts of *E. tenella* using TRIzol reagent (Invitrogen, USA) according to the manufacturer's protocol.

The recombinant plasmid *pBS-HI-3-1E* was constructed according to the procedure of previously constructed *B. subtilis* expression systems in our Lab (Fu et al. 2008). The complete *E. tenella* 3-1E open reading frame (GenBank accession number EF069437) was amplified with the following primers: 5P31E-BS(5'-ggcCTGCAGCGATGGGTGAAG

AGGCTGATACT-3'), 3P31E-BS(5'-ggcAAGCTTAGTGATGGTGATGGTGATGGAAGCCGCCCTGGTACAGGT-3') (the restriction sites are in italics and the six-His-tag codons are underlined; the specific primers used for PCR amplification were synthesized by Invitrogen Biotechnology Co., Ltd.), and the fragment was inserted into the *pBS-HI* vector which was constructed as described in Fu et al. (2008) to generate recombinant plasmid *pBS-HI-3-1E*.

Competent cells of *B. subtilis* WB600 were transformed by electroporation (Xue et al. 1999) with the *pBS-HI-3-1E* and an empty vector *pBS-HI* (control). After restriction analysis and nucleotide sequencing, the positive plasmids were verified, and the single colonies of transformants were incubated in Luria-Bertani (LB) broth at 37 °C for 8, 12, 16, 20, and 24 h to investigate the optimum expression time.

Detection of the expression of 3-1E protein in *B. subtilis* WB600

The recombinant *B. subtilis* WB600 strain harboring *B.S-pBS-HI* and *B.S-pBS-HI-3-1E* plasmid were harvested and centrifuged at 5000 \times g and 4 °C for 10 min. The supernatant was resuspended in SDS-PAGE loading buffer and analyzed on 15 % SDS-polyacrylamide gels. The sorted proteins were transferred to nitrocellulose membranes, which were incubated with an anti-His-tag antibody. The amount of secreted 3-1Erec90(a0(ei)9

replicates in each ($n=15$) group and reared in an electrically heated battery and fed with coccidiostat-free, non-medicated broiler ration, and water ad libitum. The basal diet (Table 1) is formulated according to the nutrient requirements for broilers as recommended by the NRC (1994). All experiments related to animals were conducted according to guidelines of Animal Care Committee of Animal Science College, Zhejiang University.

The wild-type strains of *E. tenella* oocysts isolated in Haining's Hatchery, Chia Tai Broiler chicken farm, Zhejiang, China, were used in the present study. Oocysts were resuspended in phosphate buffered saline (PBS pH 7.2) separated using centrifugation (5000g, 10 min) and washed three times with PBS. Then, oocysts were incubated in 2.5 % potassium dichromate at 28 °C. Sporulated oocysts were stored in 2.5 % potassium dichromate at 4 °C, and oocysts numbers were calculated using a hemocytometer prior to experimental infections.

E xperimental design and immunization procedure

The unchallenged unimmunized control group (CK1, negative control) and challenged unimmunized control group (CK2, positive control) were fed with basal diet. After acclimatization, 7-day-old chickens of the *B.S-pBS-H1* and *B.S-pBS-H1-3-1E*

mucosa secretory IgA (sIgA) were measured according to manufacturer's instructions (ADL, Atlantic Diagnostic Laboratories, Bensalem, PA, USA) by an indirect double antibody sandwich ELISA. Briefly, 96-well microtiter plate was coated overnight with 100 μ l/well (10 μ g/ml) recombinant coccidial antigen 3-1E in carbonate buffer (pH 9.6) at 4 °C. The plates were washed with PBS containing 0.05 % Tween-20 (PBST), wells blocked with blocking buffer for 1 h at 37 °C, and washed again. Samples (100 μ l) were added and incubated for 1 h at 37 °C with continuous gentle shaking. After four washes with PBST, plates were incubated for 2 h at 37 °C with 100 μ l/well of HRP-conjugated rabbit anti-chicken IgA (Sigma). After washing, the substrate solution was added (100 μ L/well). After incubation for 20 min at 37 °C, the reaction was stopped by addition of 0.5 N sulfuric acid. An automated microtiter plate reader monitored reaction at 450 nm.

Statistical analysis

Data analysis was carried out using SPSS 15.0 for windows (SPSS Inc., Chicago, IL, USA) and expressed as mean \pm SD. Means were compared using one-way analysis of variance (ANOVA) followed by Duncan's multiple range tests. Statistical significance between two groups was calculated at $P < 0.05$.

Results

High-level expression and secretion of 3-1E protein in *B. subtilis* WB600

The presence of *E. tenella* 3-1E in *B. subtilis* was analyzed. As shown in Fig. 1a, There was obviously a specific band at the position equivalent to a molecular mass of 20 kDa by SDS-PAGE. A similar band of the expected size, 20 kDa (Fig. 1b), was observed from the cell-free supernatant of the recombinant *B. subtilis* (*B.S-pBS-HI-3-1E*) by Western blot. On extrapolation of BandScan, the amount of 3-1E protein accumulated by *B. subtilis* cell reached a maximum level (c. 623 mg/l) in crude culture supernatant after 24 h of cultivation and remained at a relatively stable level for further incubation (data not shown). MALDI-TOF MS and MS/MS analysis showed the distinct band contained sequences that matched *E. tenella* 3-1E protein (protein MW 18,512, protein score C. I. % 98.628, Table S1).

Protective effects of *B.S-pBS-HI-3-1E* spore against *E. tenella* challenge

No dead chickens were found in any group after *E. tenella* challenge. Average body weight gain, relative body weight gain (%), oocyst decrease ratio, oocysts per gram (OPG), mean lesion scores, and anti-coccidial index (ACI) were described in

Table 2. Chickens in the infected unimmunized group had significantly lower average body weight gain and ACI, higher OPG, mean lesion scores than those in the uninfected unimmunized and *B.S-pBS-HI-3-1E* group ($P < 0.05$). Significantly OPG and oocyst decrease ratio were observed in the *B.S-pBS-HI* group compared with infected unimmunized group. No significant difference in ACI between infected unimmunized and *B.S-pBS-HI* groups was recorded. Chickens orally immunized with *B.S-pBS-HI-3-1E* spores showed significantly higher average weight gains and the ACI (189.2), higher OPG, and mean lesion scores than those of infected chickens that were non-immunized or immunized with *B.S-pBS-HI* ($P < 0.05$).

C tokine levels in cecal mucosa

As shown in Fig. 2, at 17 days, immunized with *B. subtilis* WB600 with empty plasmid (*B.S-pBS-HI*) had significantly elevated IL-2, Th2 key cytokines IL-4 regulatory cytokines, anti-inflammatory IL-10, and the pro-inflammatory cytokine IL-6 levels compared with any other groups ($P < 0.05$). Th1 signature cytokine IFN- γ level in *B.S-pBS-HI-3-1E* and *B.S-pBS-HI* strains were significantly lower than in the CK1 ($P < 0.05$). Interestingly, *B.S-pBS-HI-3-1E* strain significantly decreased the anti-inflammatory cytokines IL-4 level and increased the production of IL-12 ($P < 0.05$).

As shown in Fig. 2, in response to *B. subtilis* WB600 harboring 3-1E protein, the higher IL-2 level in chickens was observed at 24 days post infection ($P < 0.05$). *B.S-pBS-HI-3-1E* significantly increased IL-10 and IL-12 levels compared with the CK2 and *B.S-pBS-HI* group. Moreover, *B.S-pBS-HI-3-1E* strain could stimulate IFN- γ secretion compared with the CK2 group ($P < 0.05$).

Effect of oral administration of *B.S-pBS-HI-3-1E* strain on cecal mucosa secretor IgA responses

As indicated in Fig. 3, before infection, the 3-1E-specific sIgA concentration was significantly increased ($P < 0.05$) in the *B.S-pBS-HI* and *B.S-pBS-HI-3-1E* group compared with the CK1 group. By contrast, *B.S-pBS-HI* strain was more effective in enhancing 3-1E-reactive sIgA levels compared with *B.S-pBS-HI-3-1E* strain ($P < 0.05$).

Following infection with *E. tenella*, immunized with *B. subtilis* WB600 harboring 3-1E protein increased sIgA in cecal mucosa levels compared with other groups ($P < 0.05$; Fig. 3). However, there was no difference between group immunized with *B.S-pBS-HI* and infected unimmunized group.

Discussion

3-1E antigen was presented on the outer surface of both sporozoites and merozoites in *Eimeria* life cycle. Vaccination




Fig. 1 SDS-PAGE and western blot analysis of secreted 3-1E in the culture supernatant of recombinant *B. subtilis* WB600 strain. **a** SDS-PAGE analysis, lane M, molecular mass marker, lanes 1–2, *B.S-pBS-HI* supernatant cultures at 24 h (negative control); lanes 3–4, *B.S-pBS-HI-3-1E* supernatant cultures at 24 h. **b** Western blot analysis, lanes 1–5,

B. subtilis WB600 (*pBS-HI-3-1E*) supernatant cultures at 8, 12, 16, 20, and 24 h, respectively. Lane 6, *B. subtilis* WB600 (*pBS-HI*) supernatant cultures at 24 h (negative control). Twenty microliters of supernatant cultures loaded per lane

with the recombinant *Eimeria* 3-1E protein could significantly affect both the cellular-mediated and mucosa-associated immune responses to live *Eimeria* species (Jang et al. 2011). *E. tenella* sporozoite/merozoites antigen was originally expressed in *Escherichia coli* (Subramanian et al. 2008; Jang et al. 2010; Zhao et al. 2011), but use of *B. subtilis* to express 3-1E protein has not been reported before. A potential advantage of *B. subtilis* spores as vaccine vehicles is that bacterial spores are naturally resistant to different environmental stresses, such as extremely heat and pH. In addition, *B. subtilis* has an immense capacity for secreting proteins and is also readily adaptable to genetic manipulation (Ferreira et al. 2005). Secretory form of lipase (Heydari et al. 2013), envelope protein VP28, the most abundant exposed protein in the WSSV envelope (Fu et al. 2008) were successfully expressed in *B. subtilis*. Paccez et al. (2007) have reported that *B. subtilis* vaccine strains encoding the B subunit of the heat-labile toxin (LTB) could elicit both systemic IgG and secreted IgA response to LTB in mice (Paccez et al. 2007). In this experiment, the recombinant *B. subtilis* expressing 3-1E gene was constructed successfully. Western blot and MALDI-TOF mass

spectrometer result confirmed the 3-1E protein. The mass matches the theoretical value (Fig. 1b, Table S1).

Challenge at a dose of 5.0×10^4 sporulated *E. tenella* oocysts could cause apparent intestinal damage and induce growth depression, which is consistent with the observations made by Ma et al. (2013). The findings of the present study showed that oral immunization with *B.S-pBS-HI-3-1E* strain offered more protection against homologous infection, as demonstrated by increased average body weight gain, reduced oocyst decrease ratio (63.70 %), higher ACI, and lower average lesion scores. These results could be explained by the fact that secretion of the encoded antigen did result in significant induction of 3-1E-specific immune responses, which could effectively block the invasion of sporozoites or merozoites into the intestinal epithelial cells to reduce the damage of chicken gut tissue (Ma et al. 2011). However, the protective efficacy against *E. tenella* challenge recorded in chickens immunized with oral vaccine *B.S-pBS-HI-3-1E* was lower than previous reported vaccines based on 3-1E antigen including DNA vaccine (Min et al. 2001) and plant vaccine (Sathish et al. 2012). A possible explanation for this

Table 2 Protective effects of the constructed *B.S-pBS-HI-3-1E* strain against experimental infection of *E. tenella* chickens

Items	Average body weight gains (g)	Relative body weight gains (%)	Oocyst production ($\times 10^6$)	Lesion decrease ratio (%)	Mean lesion scores	Anti-coccidial index (ACI)
Unchallenged control	208.0 \pm 12.73a	100.0a	0.00d	100a	0.00c	206.4 \pm 4.72a
Challenged control	131.6 \pm 12.17c	63.3 \pm 5.85c	4.50 \pm 0.03a	0d	2.4 \pm 0.24a	159.3 \pm 8.46c
B.S-pBS-HI	134.2 \pm 9.03c	64.5 \pm 4.34c	2.47 \pm 0.03b	45.17 \pm 0.77c	2.2 \pm 0.20a	164.7 \pm 6.96c
B.S-pBS-HI-3-1E	165.0 \pm 8.76b	79.3 \pm 4.21b	1.63 \pm 0.12c	63.70 \pm 2.68b	1.0 \pm 0.00b	189.2 \pm 1.13b

The values represent mean \pm SD. Significant difference ($P < 0.05$) between numbers with different lowercase letters. No significant difference ($P > 0.05$) between numbers with the same letter. Average lesion score in cecum of chickens was investigated at 24 days of age. Unchallenged control=unchallenged unimmunized group, challenged control=challenged unimmunized group




Fig. 2 Cytokines level in cecal mucosa of IL-2, IL-4, IL-6, IL-10, IL-12, and INF-γ were calculated at 17 and 24 days. Each bar represents the mean±SD value (N=15). Significant difference (P<0.05) between

numbers with different letters. No significant difference (P>0.05) between numbers with the same letter

investigation might be that partial degradation of the expressed protein may result in reduced immunogenicity before reaching the intestine following oral immunization. Future studies on the improvements in the performance of

B. subtilis-based vaccine vehicle involving immunogenicity should be pursued.

The antigen load of a vaccine vehicle, especially live carrier, is a key factor affecting immunogenicity particularly following delivery via the oral route. As robust life forms, *B. subtilis* spores could resist to the gastrointestinal environment, colonize, and conduct the entire life cycle within the animal gastrointestinal tract before being excreted (Fu et al. 2008). Mucosal vaccination via the oral or ocular routes normally favors the generation of neutralizing sIgA antibodies and protective cell-mediated immune responses (Wang et al. 2004). In this study, our results demonstrated that before infection, chickens in *B.S-pBS-H1* group also showed higher sIgA level. *B. subtilis* WB600 as live carrier possibly exert their probiotic action to enhance immune protection. Post infection, we observed that orally vaccination with the recombinant *B. subtilis* WB600 harboring 3-1E protein strain induced significantly cecal mucosa sIgA response compared to




Fig. 3 Secretory IgA of cecal mucosa responses was determined by ELISA at 17 days of age and 24 days of age of chickens. Each bar represents the mean±SD value (N=15). Values with different letters differ within time point at P<0.05

any other group. Increased level of sIgA or IgY antibodies in the gut was also seen in chickens immunized with a profiling/adjuvant complex (Lillehoj et al. 2004; Lee et al. 2009; Jang et al. 2011). These results strongly suggested that secretion of the encoded antigen did result in significant induction of 3-1E-specific humoral immune responses of chickens.

Previous studies showed that *E. tenella* stimulated CD4+ T cells, macrophage response, and an increase in the IL-2, IL-4, IL-8, IL-10, IL-18, and INF- γ response in the cecum (Cornelissen et al. 2009; Zhang et al. 2012a). A protective immune response can be stimulated as either a humoral-mediated (Th2) response or a cell-mediated (Th1) response, depending on the combination of cytokines generated (Mosmann and Sad 1996). IL-2 might be relevant to the enhanced CD4+ frequencies as an inducer for T-cell proliferation found in the cecum of an *E. tenella* infection at d 6 (Cornelissen et al. 2009). Jang et al. (2010) reported that subcutaneous injection of the recombinant 3-1E protein increased levels of gene transcripts encoding INF- γ and enhanced protective immunity to *E. acervulina* challenge. The current study showed that immunization with *B. subtilis* WB600 harboring 3-1E protein stimulated the IL-2 cytokine and INF- γ secretion compared with infected unimmunized group at 7 days post infection. These cytokines are belonging to the cellular set of the immune response (Th1) (Jang et al. 2010). INF- γ expression is a common marker of cellular immunity against avian coccidiosis mediated by CD4+ and CD8+ effector lymphocytes (Choi et al. 1999; Yun et al. 2000; Cornelissen et al. 2009). These finding indicates that local cell-mediated immunity was activated. Before infection, we also observed an early cellular response manifested by the higher IL-2, IL-4, IL-6, and IL-10 cytokines ratios in ceca mucosal treated with *B. subtilis* WB600 harboring empty vector as compared to other groups. It might be attributed to local immunostimulation caused by feeding the probiotic bacteria even before the challenge (Dalloul et al. 2003) and activated humoral immune response resulting from the oral administration of *B. subtilis* as an adjuvant. It is noted that *B. subtilis* WB600 harboring 3-1E protein increased IL-10 and IL-12 production. Possibly Th2-type cytokines, IL-10 by reducing the level of Th1-type cytokines in the gut perform a regulatory role to induce immune-mediated protection (Inagaki-Ohara et al. 2006), while IL-12 also plays a critical role during *Eimeria* infection by promoting the early production of INF- γ (Lillehoj and Lillehoj 2000). These studies showed that cytokines produced via the innate immune system could regulate host protective immunity (major in cell-mediated immunity) against *E. tenella* infection (Zhang et al. 2012b).

B. subtilis-based vaccine vehicles carrying antigen of 3-1E induce humoral and local cell-mediated immunity responses against *E. tenella*. Nonetheless, future studies are needed to further shed light on the mechanism of this action before this efficient antigen expression systems could be effectively used

in the development of vaccine vehicles for other poultry diseases.

Conclusion

In conclusion, 3-1E protein was successfully expressed in *B. subtilis* WB600 at a high secretion level. Orally administration of the recombinant *B. subtilis* WB600 strain carrying the 3-1E protein to the chickens could offer partial protection against homologous challenge.

Acknowledgments The present research was funded by Science and Technology Program of Zhejiang Province (No.2011C16039) and Science and Technology Program of Hangzhou (No.20120232B26). The authors also thank Zhusuo Wang (Director of Chia Tai Broiler Development Center, Zhejiang University, China) for his kind assistance with the feeding trial.

Conflict of interest The authors declare that they have no competing interest.

References

- Abi-Ghanem D, Waghela SD, Caldwell DJ, Danforth HD, Berghman LR (2008) Phage display selection and characterization of single-chain recombinant antibodies against *Eimeria tenella* sporozoites. *Vet Immunol Immunopathol* 121:58–67
- Chapman HD, Shirley MW (2003) The Houghton strain of *Eimeria tenella*: a review of the type strain selected for genome sequencing. *Avian Pathol* 32:115–127
- Choi KD, Lillehoj HS, Zalenga DS (1999) Changes in local INF-gamma and TGF-beta4 mRNA expression and intraepithelial lymphocytes following *Eimeria acervulina* infection. *Vet Immunol Immunopathol* 71(3–4):263–275
- Cornelissen JB, Swinkels WJ, Boersma WA, Rebel JM (2009) Host response to simultaneous infections with *Eimeria acervulina*, *maxima* and *tenella*: a cumulation of single responses. *Vet Parasitol* 162(1–2):58–66
- Dalloul RA, Lillehoj HS (2006) Poultry coccidiosis: recent advancements in control measures and vaccine development. *Expert Rev Vaccines* 5(1):143–163
- Dalloul RA, Lillehoj HS, Shellem TA, Doerr JA (2003) Enhanced mucosal immunity against *Eimeria acervulina* in broilers fed a Lactobacillus-based probiotic. *Poultry Sci* 82(1):62–66
- Ferreira LC, Ferreira RC, Schumann W (2005) *Bacillus subtilis* as a tool for vaccine development: from antigen factories to delivery vectors. *Ann Acad Bras Cienc* 77:113–124
- Fu LL, Li WF, Du HH, Dai W, Xu ZR (2008) Oral vaccination with envelope protein VP28 against white spot syndrome virus in *Procambarus clarkii* using *Bacillus subtilis* as delivery vehicles. *Lett Appl Microbiol* 46(5):581–586
- Fu LL, Wang Y, Wu ZC, Li WF (2011) In vivo assessment for oral delivery of *Bacillus subtilis* harboring a viral protein (VP28) against white spot syndrome virus in *Litopenaeus vannamei*. *Aquaculture* 322–323:33–38
- Heydari A, Moosazadeh Moghaddam M, Aghamollaei H, Yakhchali M, Bambaee B, Latifi A (2013) Cloning and expression of the *Bacillus pumilus* F3 lipase gene into *Bacillus subtilis* and determining of

- comparative expression level between native and recombinant enzyme. *New Cell Mol Biotech J* 3(9):67–73
- Inagaki-Ohara K, Dewi FN, Hisaeda H, Smith A, Jimi F, Miyahira M, Abdel-Aleem AS, Horii Y, Nawa Y (2006) Intestinal intraepithelial lymphocytes sustain the epithelial barrier function against *Eimeria vermiformis* infection. *Infect Immun* 74(9):5292–5301
- Jang SI, Lillehoj HS, Lee SH, Lee KW, Park MS, Bauchan GR, Lillehoj EP, Bertrand F, Dupuis L, Deville S (2010) Immunoenhancing effects of Montanide™ ISA oil-based adjuvants on recombinant coccidia antigen vaccination against *Eimeria acervulina* infection. *Vet Parasitol* 172(3–4):221–228
- Jang SI, Lillehoj HS, Lee SH, Lee KW, Lillehoj EP, Bertrand F, Dupuis L, Deville S (2011) Mucosal immunity against *Eimeria acervulina* infection in broiler chickens following oral immunization with profilin in Montanide™ adjuvants. *Exp Parasitol* 129(1):36–41
- Johnson J, Reid WM (1970) Anticoccidial drugs: lesion scoring techniques in battery and floor-pen experiments with chickens. *Exp Parasitol* 28(1):30–36
- Lee SH, Lillehoj HS, Dalloul RA, Park DW, Hong YH, Lin JJ (2007) Influence of *Pediococcus*-based probiotic on coccidiosis in broiler chickens. *Poultry Sci* 86(1):63–66
- Lee SH, Lillehoj HS, Park DW, Jang SI, Morales A, Garcia D, Lucio E, Larios R, Victoria G, Marrufo D, Lillehoj EP (2009) Protective effect of hyperimmune egg yolk IgY antibodies against *Eimeria tenella* and *Eimeria maxima* infections. *Vet Parasitol* 163:123–126
- Lee S, Belitsky BR, Brinker JP, Kerstein KO, Brown DW, Clements JD, Keusch GT, Tzipori S, Sonenshein AL, Herrmann JE (2010a) Development of a *Bacillus subtilis*-based rotavirus vaccine. *Clin Vaccine Immunol* 17:1647–1655
- Lee SH, Lillehoj HS, Jang SI, Lee KW, Yancey RJ, Dominowski P (2010b) The effects of a novel adjuvant complex/*Eimeria* profilin vaccine on the intestinal host immune response against live *E. acervulina* challenge infection. *Vaccine* 28(39):6498–6504
- Lillehoj HS, Lillehoj EP (2000) Avian coccidiosis. A review of acquired intestinal immunity and vaccination strategies. *Avian Dis* 44(2):408–425
- Lillehoj HS, Ruff MD (1987) Comparison of disease susceptibility and subclass-specific antibody response in SC and FP chickens experimentally inoculated with *Eimeria tenella*, *E. acervulina*, or *E. maxima*. *Avian Dis* 31(1):112–119
- Lillehoj HS, Min W, Dalloul RA (2004) Recent progress on the cytokine regulation of intestinal immune responses to *Eimeria*. *Poultry Sci* 83:611–623
- Luiz WB, Cavalcante RC, PACEZ JD, Souza RD, Sbrogio-Almeida ME, Ferreira RC, Ferreira LC (2008) Boosting systemic and secreted antibody responses in mice orally immunized with recombinant *Bacillus subtilis* strains following parenteral priming with a DNA vaccine encoding the enterotoxigenic *Escherichia coli* (ETEC) CFA/I fimbriae B subunit. *Vaccine* 26(32):3998–4005
- Ma D, Ma C, Pan L, Li G, Yang J, Hong J, Cai H, Ren X (2011) Vaccination of chickens with DNA vaccine encoding *Eimeria acervulina* 3-1E and chicken IL-15 offers protection against homologous challenge. *Exp Parasitol* 127(1):208–214
- Ma D, Gao M, Dalloul RA, Ge J, Ma C, Li J (2013) Protective effects of oral immunization with live *Lactococcus lactis* expressing *Eimeria tenella* 3-1E protein. *Parasitol Res* 112(12):4161–4167
- McDougald LR, Reid WM (1991) Coccidiosis. In: Calnek BW, Barnes HJ, Beard CW, Reid WM, Yoder HW (eds) *Diseases of poultry*. Iowa State University Press, Ames, Iowa, pp 780–797
- Min W, Lillehoj HS, Burnside J, Weining KC, Staeheli P, Zhu JJ (2001) Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against *Eimeria acervulina*. *Vaccine* 20(1–2):267–274
- Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. *Immunol Today* 17(3):138–146
- Nicholson WL, Setlow P (1990) Sporulation, germination and outgrowth. In: Harwood CR, Cutting SM (eds) *Molecular biological methods for Bacillus*. Wiley Press, Chichester, UK, pp 391–450
- Pacez JD, Luiz WB, Sbrogio-Almeida ME, Ferreira RC, Schumann W, Ferreira LC (2006) Stable episomal expression system under control of a stress inducible promoter enhances the immunogenicity of *Bacillus subtilis* as a vector for antigen delivery. *Vaccine* 24(15):2935–2943
- Pacez JD, Nguyenb HD, Luiza WB, Ferreiraa RCC, Sbrogio-Almeidac ME, Schumanb W, Ferreiraa LCS (2007) Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of *Bacillus subtilis* vaccine vehicles. *Vaccine* 25(24):4671–4680
- Sathish K, Sriraman R, Subramanian BM, Rao NH, Kasa B, Donikeni J,